title: Lorcaserin treatment allows for decreased number needed to treat for weight and glycemic parameters in week 12 responders with ≥5% weight loss.
abstract: OBJECTIVE
  Lorcaserin is a serotonin 2C receptor agonist approved for chronic weight management. This analysis explores the number of patients needed to be treated (NNT) with lorcaserin for one more patient to achieve weight loss and glycemic goals.
  
  
  METHODS
  This is a post hoc analysis of three Phase 3 studies in adults with and without type 2 diabetes mellitus (T2DM) treated with lorcaserin 10 mg BID or placebo. NNT is reported for patients achieving ≥5% or ≥10% weight loss, achievement of either HbA1c <5.7% or FPG <100 mg/dL in patients with prediabetes, and reduction of HbA1c to <7% in patients with T2DM at Week 52.
  
  
  RESULTS
  In the modified intention-to-treat (MITT) population, NNTs for ≥5% and ≥10% weight loss were 3.6 and 6.2 (without T2DM) and 4.3 and 7.5 (with T2DM); in Week 12 responders (≥5% weight loss at Week 12), NNTs were 1.7 and 2.6 (without T2DM) and 1.9 and 3.2 (with T2DM). In patients with prediabetes, NNTs to achieve HbA1c <5.7% were 9.9 (MITT) and 5.2 (Week 12 responders). In patients with T2DM, NNTs to achieve HbA1c <7% were 4.2 (MITT) and 2.3 (Week 12 responders).
  
  
  CONCLUSIONS
  In addition to weight management, lorcaserin improved glycemic control in patients with prediabetes and facilitated targeted HbA1c reduction in patients with T2DM, especially for those who achieved ≥5% weight loss by Week 12. Assessment of treatment response at Week 12 is a valuable tool to achieve efficient use of healthcare resources.
  
  
  BACKGROUND
  www.clinicaltrials.gov identifiers are NCT00395135, NCT00603291, and NCT00603902.
authors.affiliation: a Metabolic Institute of America , Tarzana , CA , USA.
authors.forename: Yehuda
authors.initials: Y
authors.lastname: Handelsman
authors.affiliation: b Department of Medical and Scientific Affairs , Formerly of Eisai Inc. , Woodcliff Lake , NJ , USA.
authors.forename: Randi
authors.initials: R
authors.lastname: Fain
authors.affiliation: c Department of Health Economics & Outcomes Research, Eisai Inc. , Woodcliff Lake , NJ , USA.
authors.forename: Zhixiao
authors.initials: Z
authors.lastname: Wang
authors.affiliation: c Department of Health Economics & Outcomes Research, Eisai Inc. , Woodcliff Lake , NJ , USA.
authors.forename: Xuan
authors.initials: X
authors.lastname: Li
authors.affiliation: d Department of Diabetes and Endocrinology , Scripps Clinic , La Jolla , CA , USA.
authors.forename: Ken
authors.initials: K
authors.lastname: Fujioka
authors.affiliation: e Department of Clinical Development , Formerly of Arena Pharmaceuticals, Inc. , San Diego , CA , USA.
authors.forename: William
authors.initials: W
authors.lastname: Shanahan
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D001552:Benzazepines / Q000008:administration & dosage / Q000627:therapeutic use*; D001786:Blood Glucose / Q000187:drug effects; D015992:Body Mass Index; D001835:Body Weight / Q000187:drug effects; D015897:Comorbidity; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D015444:Exercise; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000188:drug therapy*; D011236:Prediabetic State / Q000188:drug therapy*; D058826:Serotonin 5-HT2 Receptor Agonists / Q000008:administration & dosage / Q000627:therapeutic use*; D015431:Weight Loss / Q000187:drug effects; D055815:Young Adult
chemical_list: D001552:Benzazepines; D001786:Blood Glucose; D007004:Hypoglycemic Agents; D058826:Serotonin 5-HT2 Receptor Agonists; C506658:lorcaserin
keywords: Lorcaserin; glycemic benefits; number needed to treat; weight management